Department of Biomedical Engineering, State University of New York (SUNY) at Stony Brook, Stony Brook, NY.
Transl Oncol. 2012 Dec;5(6):408-14. doi: 10.1593/tlo.12277. Epub 2012 Dec 1.
The unambiguous demarcation of tumor margins is critical at the final stages in the surgical treatment of brain tumors because patient outcomes have been shown to correlate with the extent of resection. Real-time high-resolution imaging with the aid of a tumor-targeting fluorescent contrast agent has the potential to enable intraoperative differentiation of tumor versus normal tissues with accuracy approaching the current gold standard of histopathology. In this study, a monoclonal antibody targeting the vascular endothelial growth factor receptor 1 (VEGFR-1) was conjugated to fluorophores and evaluated as a tumor contrast agent in a transgenic mouse model of medulloblastoma. The probe was administered topically, and its efficacy as an imaging agent was evaluated in vitro using flow cytometry, as well as ex vivo on fixed and fresh tissues through immunohistochemistry and dual-axis confocal microscopy, respectively. Results show a preferential binding to tumor versus normal tissue, suggesting that a topically applied VEGFR-1 probe can potentially be used with real-time intraoperative optical sectioning microscopy to guide brain tumor resections.
肿瘤边界的明确划定在脑肿瘤的手术治疗的最后阶段至关重要,因为患者的预后与切除的范围有关。借助肿瘤靶向荧光对比剂的实时高分辨率成像有可能实现术中区分肿瘤与正常组织,其准确性接近组织病理学的当前金标准。在这项研究中,一种针对血管内皮生长因子受体 1 (VEGFR-1)的单克隆抗体与荧光团缀合,并在成神经管细胞瘤的转基因小鼠模型中作为肿瘤对比剂进行了评估。该探针以局部方式给药,并通过流式细胞术在体外以及通过免疫组织化学和双轴共聚焦显微镜分别在固定和新鲜组织上进行评估,作为成像剂的功效。结果表明,与正常组织相比,探针优先与肿瘤结合,这表明局部应用的 VEGFR-1 探针可潜在地与实时术中光学切片显微镜一起用于指导脑肿瘤切除术。